Evrysdi (Risdiplam uses)
Evrysdi (Risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier used for the treatment of spinal muscular atrophy (SMA) in patients aged 2 months and older.
Dosage: The recommended dose of Risdiplam is determined by age and body weight. The recommended daily dosage for patients aged 2 months to less than 2 years is 0.2 mg/kg, for patients aged 2 years and older weighing less than 20 kg is 0.25 mg/kg, and for patients aged 2 years and older weighing 20 kg or more is 5 mg. The risdiplam dosage is taken orally once daily after a meal at around the same time each day. Patients should drink water after taking Risdiplam to ensure the drug has been completely swallowed. In case the patient is not able to swallow and has a nasogastric or gastrostomy tube, Risdiplam can be administered via the tube. The tube must be flushed with water after delivering Risdiplam. In case a dose of Risdiplam is missed, it should be administered as soon as possible if still within six hours of the missed dose, and the usual dosing schedule can be resumed on the next day. Otherwise, the missed dose needs to be skipped, and the next dose should be administered at the regularly scheduled time on the next day.
Side Effects: The most commonly reported evrysdi side effects include:
- Ulcers of the mouth area
- Joint pain (arthralgia)
- Urinary tract infections
Warnings and Precautions:
In infants who are breastfed, Risdiplam should be administered after breastfeeding. Risdiplam cannot be mixed with formula or milk. Patients or caregivers are advised to prepare the dose using the reusable oral syringe provided. The evrysdi 60 mg must be taken immediately after it is drawn up into the oral syringe. If it is not taken within 5 minutes, it should be discarded from the oral syringe, and a new dose should be prepared. Pregnant women and women of reproductive potential are advised that, based on animal studies, Risdiplam may cause fetal harm. Male patients are advised that their fertility may be compromised while on treatment with Risdiplam 60 mg.